Chengdu Olymvax Biopharmaceuticals Inc. A

SHG:688319 China Biotechnology
Market Cap
$1.73 Billion
CN¥12.70 Billion CNY
Market Cap Rank
#7093 Global
#1171 in China
Share Price
CN¥31.31
Change (1 day)
+0.06%
52-Week Range
CN¥12.79 - CN¥33.17
All Time High
CN¥40.86
About

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was fou… Read more

Chengdu Olymvax Biopharmaceuticals Inc. A - Asset Resilience Ratio

Latest as of September 2025: 2.45%

Chengdu Olymvax Biopharmaceuticals Inc. A (688319) has an Asset Resilience Ratio of 2.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
CN¥47.60 Million
Cash + Short-term Investments
Total Assets
CN¥1.94 Billion
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Chengdu Olymvax Biopharmaceuticals Inc. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Chengdu Olymvax Biopharmaceuticals Inc. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥47.60 Million 2.45%
Total Liquid Assets CN¥47.60 Million 2.45%

Asset Resilience Insights

  • Limited Liquidity: Chengdu Olymvax Biopharmaceuticals Inc. A maintains only 2.45% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Chengdu Olymvax Biopharmaceuticals Inc. A Industry Peers by Asset Resilience Ratio

Compare Chengdu Olymvax Biopharmaceuticals Inc. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Chengdu Olymvax Biopharmaceuticals Inc. A (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Chengdu Olymvax Biopharmaceuticals Inc. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.97% CN¥17.50 Million CN¥1.81 Billion +0.97pp
2023-12-31 0.00% CN¥100.00 CN¥1.61 Billion -6.09pp
2022-12-31 6.09% CN¥90.00 Million CN¥1.48 Billion -10.42pp
2021-12-31 16.50% CN¥200.00 Million CN¥1.21 Billion +14.94pp
2020-12-31 1.56% CN¥10.00 Million CN¥641.26 Million --
pp = percentage points